Trending:
Analysis
-
![]()
Blocking generic competition: will naming and shaming work?
The US Food and Drug Administration (FDA) has publicly listed the names of nearly 40 pharma companies that may have been denying access to reference samples for generic drug manufacturers,...
-
![]()
Opening up the Chinese drug market
The Chinese pharma market has always been inward-looking, with foreign investors deterred by an unfavorable regulatory climate. However, the government has implemented a raft of reforms with a view to...
-
![]()
June’s top news stories
Novartis completed the sale of its 36.5% stake to GSK in its consumer healthcare joint venture for $13bn, and the UK Government revealed plans to build a fully automated facility...
-
![]()
Is the UK’s drug evaluation system in need of an overhaul?
A recent parliamentary debate surrounding access to Orkambi, a new treatment for cystic fibrosis, elicited some scathing remarks about NICE, the medical board responsible for introducing new drugs in the...
-
![]()
Malaria eradication: tackling counterfeit and substandard drugs
Although malaria is beginning to be eradicated, it remains a global health issue and this is partially due to the existence of counterfeit and substandard drugs in the regions where...
-
![]()
Pharma Technology Focus – Issue 72
In this issue: Overcoming red tape in China, how to boost adoption of biosimilars in the US, a profile of global health research network TriNetX, unlocking cell-free protein synthesis, and...
-
![]()
Shaky foundations: the flaws in animal research reporting
A new systematic analysis has reiterated concerns over the quality of reporting for preclinical efficacy data from animal studies. With these findings in mind, what are the flaws in animal...
-
![Johnson & Johnson]()
The world’s biggest pharmaceutical companies by revenue in 2018
Pharmaceutical companies with anti-retroviral and oncology therapies in their portfolio emerged as the biggest revenue generators in 2017. Research and development efforts have helped the biggest companies to lead despite...
-
![]()
Talking generics in the UK with Mylan’s Jean-Yves Brault
Following the recent UK launch by Mylan of Brabio, the first generic version of Teva’s Copaxone for multiple sclerosis, we spoke to Mylan’s UK Country Manager Jean-Yves Brault about the...
-
![]()
Innovators to watch from TLA’s HealthTech Innovator conference
Tech London Advocates and the Health Foundry organised the HealthTech Innovator conference which showcased promising companies working in the pharmaceutical field, whcih are launching new products and are seeking investment....
